Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of BI 1060469 Formulations in Healthy Females
NCT02438696Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 1060469 in asthma (6 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point and Maximum measured concentration of the analyte in plasma. Started May 2015; status: completed.
02
Drugs
BI 1060469
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02438696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02438696.